At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Etokimab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma
In Brief
A Phase 2 clinical trial evaluating Etokimab and Placebo for Eosinophilic Asthma. Completed, enrolled 25 participants across 7 sites in 2 countries.
Detailed Summary
This is a proof of concept study designed to assess the effects of a single intravenous dose of etokimab compared to placebo in adult participants with severe eosinophilic asthma. This study will also assess the safety and tolerability of etokimab in adult participants with severe eosinophilic asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Asthma
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedMar 2018
Primary CompletionOct 2018
TodayJul 2026
First PostedMar 19, 2018
Enrollment StartNov 14, 2017
Primary CompletionOct 30, 2018
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 8.3 years ago
Interventions
Etokimabbiological
Administered on Day 1 over 1 hour by IV infusion
Placebodrug
Administered on Day 1 over 1 hour by IV infusion